Skip to main content
ANAGENICS LIMITED logo

ANAGENICS LIMITED — Investor Relations & Filings

Ticker · AN1 ISIN · AU0000198095 ASX Manufacturing
Open in API
Filings indexed 1,067 across all filing types
Latest filing 2018-07-30 Capital/Financing Update
Country AU Australia
Listing ASX AN1

About ANAGENICS LIMITED

https://anagenics.com

Anagenics Limited is a health and wellness company focused on the development and commercialization of science-based anti-aging and longevity solutions. The company specializes in the research and distribution of clinically validated products targeting hair loss and skin health. Its core portfolio includes the évolis brand, which utilizes proprietary FGF5 inhibitor technology to promote hair growth and improve hair health. Through its subsidiaries, such as Advangen and BLC Cosmetics, the company manages a diverse range of premium skincare and wellness brands. Anagenics operates across international markets, providing consumer-facing products and professional-grade treatments backed by scientific research. The company's strategic focus remains on expanding its presence in the global beauty-tech and wellness sectors by leveraging its intellectual property and distribution networks.

Recent filings

Filing Released Lang Actions
Cellmid Share Placement Raises $9M 3 pages 101.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement detailing a share placement raising $9.0 million, including specifics about the placement tranches, share purchase plan, use of proceeds, and key dates. It focuses on capital raising activities, share issuance, and shareholder approval processes. There are no financial statements or detailed financial performance data presented, nor is it a report or transcript. The content clearly relates to financing and capital structure changes. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length (8616 characters) and detailed content support this classification with high confidence.
2018-07-30 English
Cellmid Share Purchase Plan 5 pages 154.3KB
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement and explanatory letter regarding a Share Purchase Plan (SPP) offered by Cellmid Limited to its shareholders. It includes terms and conditions, subscription details, eligibility criteria, timetable, and instructions for participation. The content focuses on a capital raising activity through issuing additional shares to existing shareholders at a discounted price. There are no financial statements, earnings data, or management discussion of financial results. The document is not a report but an announcement and offer related to capital raising. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief notice or a regulatory filing but a substantive update on financing activity.
2018-07-30 English
Trading Halt 2 pages 146.3KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Cellmid Limited dated 27 July 2018, requesting a trading halt pending a further announcement related to a proposed capital raising. The text explicitly states the halt is requested due to a capital raising announcement that is material to the company. There are no financial statements or detailed financial data present, only a notice of trading halt and the reason for it. This fits the category of a Capital/Financing Update (CAP) as it relates to fundraising activities and capital structure changes. The document is short and does not contain a full report or financial results, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a Regulatory Filing (RNS) because it is a specific market announcement about capital raising. Therefore, the correct classification is CAP with high confidence.
2018-07-26 English
CELLMID UPDATES ON DISTRIBUTION OF EVOLIS 3 pages 176.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Cellmid Limited providing updates on the distribution and marketing of its évolis® product line, including new store placements, product launches, and expected sales impacts. It contains no financial statements, detailed financial analysis, or regulatory filings such as annual or quarterly reports. It is a corporate update focused on business developments and sales channels rather than financial results or governance matters. The document length is 7,430 characters, which is sufficient for a detailed announcement but does not contain financial data or management discussion typical of financial reports. Therefore, it fits best into the category of a Capital/Financing Update (CAP) as it relates to business expansion and expected revenue impact from distribution changes.
2018-07-10 English
CELLMID INVESTOR PRESENTATION 30 pages 2.5MB
Investor Presentation Classification · 95% confidence The document is titled 'INVESTOR PRESENTATION' and includes detailed information about the company's products, market opportunities, board members, growth drivers, and distribution agreements. It is structured as a presentation aimed at investors, focusing on business strategy, product portfolio, market positioning, and financial highlights. There is no indication that this is a formal regulatory filing, annual or quarterly report, or an announcement of voting results or legal matters. The content is consistent with an investor presentation rather than a formal report or announcement. The document length is substantial (15,000 characters), supporting a detailed presentation rather than a brief announcement. Therefore, the appropriate classification is Investor Presentation (IP).
2018-07-01 English
MIDKINE SYMPOSIUM MUNICH 3 pages 296.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement reporting on the 5th Midkine Symposium held by Cellmid Limited. It provides detailed information about the symposium's presentations, research findings, and strategic implications for the company's biotechnology assets. The content is focused on scientific and clinical updates rather than financial results, management changes, or regulatory filings. It is not a financial report, earnings release, or management discussion. The document is a corporate announcement about a scientific event and its implications, which fits best under the category of a general regulatory announcement rather than a specific financial or governance report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2018-05-29 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.